Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 4.33% | 154.81 | 0.0% | $1863.66m | |
| NVAX | Novavax, Inc. | 4.39% | 231.23 | 92.9% | $1423.06m | |
| OCGN | Ocugen, Inc. | 36.88% | 10.95 | 0.0% | $1213.37m | |
| AMGN | Amgen, Inc. | -1.14% | 224.92 | 1.3% | $594.80m | |
| ILMN | Illumina, Inc. | -1.45% | 439.41 | 3.5% | $530.13m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.58% | 450.57 | 2.7% | $522.91m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.20% | 212.55 | 1.9% | $515.41m | |
| GILD | Gilead Sciences, Inc. | -2.21% | 61.40 | 1.0% | $485.52m | |
| BIIB | Biogen, Inc. | -1.58% | 272.88 | 1.7% | $380.18m | |
| BNGO | BioNano Genomics, Inc. | -2.89% | 9.73 | 0.0% | $374.38m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.59% | 152.75 | 2.0% | $371.25m | |
| CRSP | CRISPR Therapeutics AG | -1.25% | 125.69 | 0.6% | $292.02m | |
| EXAS | EXACT Sciences Corp. | 3.67% | 136.12 | 18.4% | $252.07m | |
| SGEN | Seagen Inc. | 0.68% | 151.11 | 5.8% | $212.33m | |
| VXRT | Vaxart, Inc. | -4.67% | 7.15 | 0.0% | $210.57m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.